Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review
Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome
Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).
1 finding from 1 review
OR 0.56 [0.22, 1.35]
74 participants
Low
Change in 10‐metre walking time · people with fatigue in peripheral neuropathy
1 finding from 1 review
Change in 9‐hole peg test (HPT) at 12 months (seconds) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Participation · people with fatigue in peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy
1 finding from 1 review
Serious adverse events · people with fatigue in peripheral neuropathy
Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Fatigue · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in activity limitations · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participation · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
74 participants
Low
Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
80 participants
GRADE not reported
Reduction in fatigue · people with fatigue in peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · people with fatigue in peripheral neuropathy
1 finding from 1 review
Change in activity limitations · people with fatigue in peripheral neuropathy
1 finding from 1 review
Change in ankle dorsiflexion range of motion Lidcome Template in degrees. Scale from: 0.36 to 31.28. · patients with patients with reduced ankle range of motion in neuromuscular disease
1 finding from 1 review